Pulmonary adverse drug event data in hypertension with implications on COVID-19 morbidity

Abstract Hypertension is a recognized comorbidity for COVID-19. The association of antihypertensive medications with outcomes in patients with hypertension is not fully described. However, angiotensin-converting enzyme 2 (ACE2), responsible for host entry of the novel coronavirus (SARS-CoV-2) leadin...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Majid Jaberi-Douraki, Emma Meyer, Jim Riviere, Nuwan Indika Millagaha Gedara, Jessica Kawakami, Gerald J. Wyckoff, Xuan Xu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/88722c0702ca410cafac6d604c2cd4d1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:88722c0702ca410cafac6d604c2cd4d1
record_format	dspace
spelling	oai:doaj.org-article:88722c0702ca410cafac6d604c2cd4d12021-12-02T17:45:11ZPulmonary adverse drug event data in hypertension with implications on COVID-19 morbidity10.1038/s41598-021-92734-72045-2322https://doaj.org/article/88722c0702ca410cafac6d604c2cd4d12021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-92734-7https://doaj.org/toc/2045-2322Abstract Hypertension is a recognized comorbidity for COVID-19. The association of antihypertensive medications with outcomes in patients with hypertension is not fully described. However, angiotensin-converting enzyme 2 (ACE2), responsible for host entry of the novel coronavirus (SARS-CoV-2) leading to COVID-19, is postulated to be upregulated in patients taking angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs). Here, we evaluated the occurrence of pulmonary adverse drug events (ADEs) in patients with hypertension receiving ACEIs/ARBs to determine if disparities exist between individual drugs within the respective classes using data from the FDA Spontaneous Reporting Systems. For this purpose, we proposed the proportional reporting ratio to provide a statistical summary for the commonality of an ADE for a specific drug as compared to the entire database for drugs in the same or other classes. In addition, a statistical procedure, multiple logistic regression analysis, was employed to correct hidden confounders when causative covariates are underreported or untrusted to correct analyses of drug-ADE combinations. To date, analyses have been focused on drug classes rather than individual drugs which may have different ADE profiles depending on the underlying diseases present. A retrospective analysis of thirteen pulmonary ADEs showed significant differences associated with quinapril and trandolapril, compared to other ACEIs and ARBs. Specifically, quinapril and trandolapril were found to have a statistically significantly higher incidence of pulmonary ADEs compared with other ACEIs as well as ARBs (P < 0.0001) for group comparison (i.e., ACEIs vs. ARBs vs. quinapril vs. trandolapril) and (P ≤ 0.0007) for pairwise comparison (i.e., ACEIs vs. quinapril, ACEIs vs. trandolapril, ARBs vs. quinapril, or ARBs vs. trandolapril). This study suggests that specific members of the ACEI antihypertensive class (quinapril and trandolapril) have a significantly higher cluster of pulmonary ADEs.Majid Jaberi-DourakiEmma MeyerJim RiviereNuwan Indika Millagaha GedaraJessica KawakamiGerald J. WyckoffXuan XuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Majid Jaberi-Douraki Emma Meyer Jim Riviere Nuwan Indika Millagaha Gedara Jessica Kawakami Gerald J. Wyckoff Xuan Xu Pulmonary adverse drug event data in hypertension with implications on COVID-19 morbidity
description	Abstract Hypertension is a recognized comorbidity for COVID-19. The association of antihypertensive medications with outcomes in patients with hypertension is not fully described. However, angiotensin-converting enzyme 2 (ACE2), responsible for host entry of the novel coronavirus (SARS-CoV-2) leading to COVID-19, is postulated to be upregulated in patients taking angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs). Here, we evaluated the occurrence of pulmonary adverse drug events (ADEs) in patients with hypertension receiving ACEIs/ARBs to determine if disparities exist between individual drugs within the respective classes using data from the FDA Spontaneous Reporting Systems. For this purpose, we proposed the proportional reporting ratio to provide a statistical summary for the commonality of an ADE for a specific drug as compared to the entire database for drugs in the same or other classes. In addition, a statistical procedure, multiple logistic regression analysis, was employed to correct hidden confounders when causative covariates are underreported or untrusted to correct analyses of drug-ADE combinations. To date, analyses have been focused on drug classes rather than individual drugs which may have different ADE profiles depending on the underlying diseases present. A retrospective analysis of thirteen pulmonary ADEs showed significant differences associated with quinapril and trandolapril, compared to other ACEIs and ARBs. Specifically, quinapril and trandolapril were found to have a statistically significantly higher incidence of pulmonary ADEs compared with other ACEIs as well as ARBs (P < 0.0001) for group comparison (i.e., ACEIs vs. ARBs vs. quinapril vs. trandolapril) and (P ≤ 0.0007) for pairwise comparison (i.e., ACEIs vs. quinapril, ACEIs vs. trandolapril, ARBs vs. quinapril, or ARBs vs. trandolapril). This study suggests that specific members of the ACEI antihypertensive class (quinapril and trandolapril) have a significantly higher cluster of pulmonary ADEs.
format	article
author	Majid Jaberi-Douraki Emma Meyer Jim Riviere Nuwan Indika Millagaha Gedara Jessica Kawakami Gerald J. Wyckoff Xuan Xu
author_facet	Majid Jaberi-Douraki Emma Meyer Jim Riviere Nuwan Indika Millagaha Gedara Jessica Kawakami Gerald J. Wyckoff Xuan Xu
author_sort	Majid Jaberi-Douraki
title	Pulmonary adverse drug event data in hypertension with implications on COVID-19 morbidity
title_short	Pulmonary adverse drug event data in hypertension with implications on COVID-19 morbidity
title_full	Pulmonary adverse drug event data in hypertension with implications on COVID-19 morbidity
title_fullStr	Pulmonary adverse drug event data in hypertension with implications on COVID-19 morbidity
title_full_unstemmed	Pulmonary adverse drug event data in hypertension with implications on COVID-19 morbidity
title_sort	pulmonary adverse drug event data in hypertension with implications on covid-19 morbidity
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/88722c0702ca410cafac6d604c2cd4d1
work_keys_str_mv	AT majidjaberidouraki pulmonaryadversedrugeventdatainhypertensionwithimplicationsoncovid19morbidity AT emmameyer pulmonaryadversedrugeventdatainhypertensionwithimplicationsoncovid19morbidity AT jimriviere pulmonaryadversedrugeventdatainhypertensionwithimplicationsoncovid19morbidity AT nuwanindikamillagahagedara pulmonaryadversedrugeventdatainhypertensionwithimplicationsoncovid19morbidity AT jessicakawakami pulmonaryadversedrugeventdatainhypertensionwithimplicationsoncovid19morbidity AT geraldjwyckoff pulmonaryadversedrugeventdatainhypertensionwithimplicationsoncovid19morbidity AT xuanxu pulmonaryadversedrugeventdatainhypertensionwithimplicationsoncovid19morbidity
_version_	1718379599131312128

Pulmonary adverse drug event data in hypertension with implications on COVID-19 morbidity

Ejemplares similares